Process analytical technology rig and NIR spectrometer

The Food and Drug Administration is forecasting a requirement for an in-line measurement system designed for integration into a continuous tableting line, specifically targeting the implementation of process analytical technology through a NIR spectrometer. This system will enable real-time monitoring and quality control of pharmaceutical tablet production, ensuring consistent product attributes such as uniformity, composition, and potency without interrupting the manufacturing process. The equipment must support seamless compatibility with existing continuous manufacturing workflows and meet regulatory standards for data integrity, accuracy, and reliability in a GMP environment. The procurement is classified under NAICS code 334516, indicating a focus on instrumentation and laboratory equipment manufacturing. The opportunity is posted under the FDA’s Center for Drug Evaluation and Research, with the primary point of contact for program inquiries being the Cder Acquisition Liaison. While the contracting officer details are still to be determined, interested parties should monitor the official OSDBU portal for the upcoming formal solicitation, as this forecast signals the FDA’s intent to enhance its in-process quality assurance capabilities through advanced analytical instrumentation in next-generation pharmaceutical production lines.